法舒地尔联合瑞舒伐他汀治疗血管性痴呆对认知功能、C-反应蛋白及氧化应激的影响  

Effects of fasudil combined with rosuvastatin in the treatment of vascular dementia on patients' cognitive function,C-reactive protein and oxidative stress

作　　者：陈娟燕 宋水江[1] 徐冬娟 徐琼 李鸿飞 CHEN Juanyan;SONG Shuijiang;XU Dongjuan;XU Qiong;LI Hongfei(Department of Neurology,the Second Affiliated Hospital of Zhefiang University School of Medicine,Hangzhou 310009,Zhejiang,China;Department of Neurology,Dongyang People's Hospital,Dongyang 322100,Zhejiang,.China)

机构地区：[1]浙江大学医学院附属第二医院神经内科 [2]东阳市人民医院神经内科

出　　处：《中国临床药理学与治疗学》2018年第10期1153-1158,共6页Chinese Journal of Clinical Pharmacology and Therapeutics

摘　　要：目的:研究血管性痴呆(VD)给予法舒地尔联合瑞舒伐他汀治疗对其认知功能、C-反应蛋白及氧化应激的影响。方法:选取184例VD患者为研究对象,按随机数表法分为瑞舒伐他汀组与联合用药组(法舒地尔+瑞舒伐他汀),各92例。比较两组治疗前后简易精神状态量表(MMSE)、蒙特利尔认知功能量表(Mo CA)与日常生活能力量表(ADL)评分、C-反应蛋白(CRP)水平、丙二醛(MDA)、血清同型半胱氨酸(Hcy)与超氧化物歧化酶(SOD)水平、血脂指标(TC、TG、LDL-C、HDLC)水平、临床疗效及不良反应发生率。结果:联合用药组治疗总有效率(93. 48%)显著高于瑞舒伐他汀组(82. 61%),差异有统计学意义(P <0. 05);治疗后,联合用药组MMSE、MoCA与ADL量表积分明显高于瑞舒伐他汀组,CRP、MDA、Hcy、TC、TG、LDL-C水平显著低于瑞舒伐他汀组,SOD水平明显高于瑞舒伐他汀组,差异均有统计学意义(P <0. 05)。不良反应发生率无统计学意义(P> 0. 05)。结论:法舒地尔联合瑞舒伐他汀治疗VD更有利于改善患者认知功能与日常生活能力,降低C-反应蛋白水平与氧化应激反应,改善血脂指标,临床疗效显著,且安全性高。AIM: To investigate the effects of fasudil combined with rosuvastatin in the treatment of vascular dementia( VD) on patients ’ cognitive function,C-reactive protein and oxidative stress.METHODS: One hundred and eighty-four VD patients were selected as study subjects. They were divided into the rosuvastatin group and the combined drug group( fasudil + rosuvastatin) according to the random number table method. Each group contains 92 cases. MMSE( Mini-Mental State Examination),MoCA( Montreal Cognitive Assessment) and ADL( Activities of Daily Living) scores,the level of CRP( C-reactive protein), MDA( malondialdehyde),Hcy( serum homocysteine) and SOD( superoxide dismutase),as well as blood lipid index( TC,TG,LDL-C,HDL-C) levels,clinical efficacy and incidence of adverse reaction were compared between the two groups before and after treatment.RESULTS: The total effective rate of the combined drug group( 93. 48%) was significantly higher than that of the rosuvastatin group( 82. 61%),and the difference was statistically significant( P < 0. 05).After treatment,the MMSE,MoCA and ADL scores of the combined drug group were significantly higher than that of the rosuvastatin group,while the level of CRP,MDA,Hcy,TC,TG and LDL-C was significantly lower than that of the rosuvastatin group,and the SOD level was significantly higher than that of the rosuvastatin group,which were of statistically significant difference( P < 0. 05). There was no significant difference in the incidence of adverse reaction( P > 0. 05). CONCLUSION: Fasudil combined with rosuvastatin in the treatment of VD can improve patients’ cognitive function and daily living ability,reduce oxidative stress response and the level of C-reactive protein,and improve patients’ blood lipid index. This method is of significant clinical efficacy and high safety

关 键 词：血管性痴呆 法舒地尔 瑞舒伐他汀 认知功能 C-反应蛋白 氧化应激 

分 类 号：R743[医药卫生—神经病学与精神病学]